B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer

被引:100
作者
Tan, Jing [1 ,2 ]
Lee, Puay Leng [1 ]
Li, Zhimei [1 ]
Jiang, Xia [1 ]
Lim, Yaw Chyn [2 ]
Hooi, Shing Chuan [2 ]
Yu, Qiang [1 ,2 ,3 ]
机构
[1] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore
[3] DUKE NUS Grad Med Sch Singapore, Singapore, Singapore
关键词
HUMAN CELL-TRANSFORMATION; SMALL-MOLECULE INHIBITORS; PROTEIN PHOSPHATASE 2A; TUMOR-SUPPRESSOR PP2A; BETA-CATENIN; PPP2R1B GENE; PHOSPHATIDYLINOSITOL; 3-KINASE; ONCOGENIC TRANSFORMATION; COLON-CANCER; C-MYC;
D O I
10.1016/j.ccr.2010.10.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The PP2A serine/threonine protein phosphatase serves as a critical cellular regulator of cell growth, proliferation, and survival. However, how this pathway is altered in human cancer to confer growth advantage is largely unknown. Here, we show that PPP2R2B, encoding the B55 beta regulatory subunit of the PP2A complex, is epigenetically inactivated by DNA hypermethylation in colorectal cancer. B55 beta-associated PP2A interacts with PDK1 and modulates its activity toward Myc phosphorylation. On loss of PPP2R2B, mTORC1 inhibitor rapamycin triggers a compensatory Myc phosphorylation in PDK1-dependent, but PI3K and AKT-independent manner, resulting in resistance. Reexpression of PPP2R2B, genetic ablation of PDK1 or pharmacologic inhibition of PDK1 abrogates the rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization. Thus, PP2A-B55 beta antagonizes PDK1-Myc signaling and modulates rapamycin sensitivity.
引用
收藏
页码:459 / 471
页数:13
相关论文
共 51 条
[1]  
ANDRABI S, 2007, MOL CELL BIOL, V104, P2832
[2]   A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins [J].
Arnold, Hugh K. ;
Sears, Rosalie C. .
CANCER AND METASTASIS REVIEWS, 2008, 27 (02) :147-158
[3]   Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms [J].
Calin, GA ;
di Iasio, MG ;
Caprini, E ;
Vorechovsky, I ;
Natali, PG ;
Sozzi, G ;
Croce, CM ;
Barbanti-Brodano, G ;
Russo, G ;
Negrini, M .
ONCOGENE, 2000, 19 (09) :1191-1195
[4]   Identification of specific PP2A complexes involved in human cell transformation [J].
Chen, W ;
Possemato, R ;
Campbell, KT ;
Plattner, CA ;
Pallas, DC ;
Hahn, WC .
CANCER CELL, 2004, 5 (02) :127-136
[5]   Cancer-associated PP2A Aα subunits induce functional haploinsufficiency and tumorigenicity [J].
Chen, W ;
Arroyo, JD ;
Timmons, JC ;
Possemato, R ;
Hahn, WC .
CANCER RESEARCH, 2005, 65 (18) :8183-8192
[6]   mTOR and cancer therapy [J].
Easton, J. B. ;
Houghton, P. J. .
ONCOGENE, 2006, 25 (48) :6436-6446
[7]   Protein phosphatase 2A regulatory subunits and cancer [J].
Eichhorn, Pieter J. A. ;
Creyghton, Menno P. ;
Bernards, Rene .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01) :1-15
[8]   Current development of mTOR inhibitors as anticancer agents [J].
Faivre, Sandrine ;
Kroemer, Guido ;
Raymond, Eric .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :671-688
[9]   A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma [J].
Fan, Qi-Wen ;
Knight, Zachary A. ;
Goldenberg, David D. ;
Yu, Wei ;
Mostov, Keith E. ;
Stokoe, David ;
Shokat, Kevan M. ;
Weiss, William A. .
CANCER CELL, 2006, 9 (05) :341-349
[10]   Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 [J].
Feldman, RI ;
Wu, JM ;
Polokoff, MA ;
Kochanny, MJ ;
Dinter, H ;
Zhu, DG ;
Biroc, SL ;
Alicke, B ;
Bryant, J ;
Yuan, SD ;
Buckman, BO ;
Lentz, D ;
Ferrer, M ;
Whitlow, M ;
Adler, M ;
Finster, S ;
Chang, Z ;
Arnaiz, DO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) :19867-19874